Epistaxis: Prevalence and severity among Hypertensive patients attending District hospital in Tanzania
Tanzania Journal of Health Research · 28.09.2023 · 24 (4) · 425-431
DOI: 10.4314/thrb.v24i4.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tanzania Journal of Health Research, online erschienen am 28.09.2023. Verfasst von Enica Richard Massawe und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Epistaxis is one of the common ENT emergency conditions. Most of the time the bleeding is self-limited, but can be life-threatening. Serious spontaneous epistaxis may reveal underlying true hypertension in about 43% of patients with no previous history of hypertension. It can result from several causes and hypertension is among the aggravating factors.
Objective
The study aimed to determine the prevalence and severity of epistaxis among hypertensive patients. Material and method: This study was a prospective cross-sectional study conducted from October 2021 to April 2022 involving a total of 196 adult patients with hypertension at a district hospital in Tanzania. A consecutive sampling technique was employed and structured questionnaires were used to collect data. Data entry was performed using SPSS version 25 and a P value of
Zitieren
APA
Massawe, E. R., & Mkurwa, M. (2023). Epistaxis: Prevalence and severity among Hypertensive patients attending District hospital in Tanzania. Tanzania Journal of Health Research, 24(4), 425-431. https://doi.org/10.4314/thrb.v24i4.11
Vancouver
Massawe ER, Mkurwa M. Epistaxis: Prevalence and severity among Hypertensive patients attending District hospital in Tanzania. Tanzania Journal of Health Research. 2023;24(4):425-431. doi:10.4314/thrb.v24i4.11
BibTeX
@article{Massawe2023,
author = {Massawe, Enica Richard and Mkurwa, Marwa},
title = {Epistaxis: Prevalence and severity among Hypertensive patients attending District hospital in Tanzania},
journal = {Tanzania Journal of Health Research},
year = {2023},
volume = {24},
number = {4},
pages = {425--431},
doi = {10.4314/thrb.v24i4.11}
}
EUVIMED